The Journal of Clinical Investigation (JCI), a peer-reviewed, top-tier medical journal published by the American Society for Clinical Investigation, carried a commentary entitled “Schlemm’s Canal: More Than Meets the Eye, Lymphatics in Disguise” in the July 25, 2014 issue.
In the commentary, the authors compared a research paper (“Lymphatic regular PROX1 determines Schlemm’s canal integrity and identity”) by Professor Gou-Young Koh of the Graduate School of Medical Science and Engineering at KAIST with research work from the University of Helsinki (article entitled “The Schlemm’s canal is a VEGF-C/VEGFR-3 responsive lymphatic-like vessel”).
The JCI released a press statement dated July 25, 2014 on its commentary. It mentioned that glaucoma, one of the leading causes of blindness worldwide, elevates eye pressure owing to poor drainage of aqueous humor. A specialized structure called “Schlemm’s canal” funnels aqueous humor from the eye back into circulation, which is critical to prevent pressure buildup in the eye. The article discussed the role of Schlemm’s canal in the context of lymphatic vascular characteristics by reviewing two research group’s papers back-to-back.
For the full text of the press release, please visit the link below:
Press Release from the Journal of Clinical Investigation, July 25, 2014
“Researchers uncover the secret lymphatic identity of the Schlemm’s canal”
http://www.eurekalert.org/pub_releases/2014-07/joci-rut072414.php
Distinguished Professor Gou Young Koh from the Graduate School of Medical Science and Engineering was appointed a 2018 laureate in medicine of the Ho-Am Prize by the Ho-Am Foundation. Professor Koh is a renowned expert in the field of tumor angiogenesis by exploring the hidden nature of capillary and lymphatic vessels in human organs. He was recognized for demonstrating the effective reduction of tumor progression and metastasis via tumor vessel normalization. This counterintuitive stu
2018-04-11Professor Gou Young Koh in the Graduate School of Medical Science and Engineering and his team have identified a new mechanism involved in the development and progression of glaucoma, and found a potential therapeutic option to treat it. Glaucoma is the second cause of irreversible blindness, after cataracts. It affects about 3.5% of the world population aged 40 to 80. Professor Koh also serves as the director of the Center for Vascular Research at the Institute for Basic Science. The IBS said
2017-09-19